A global clinical trial co-led by McMaster University has found that fluvoxamine, a widely available and low-cost antidepressant, significantly reduces fatigue and improves quality of life in adults with long COVID. The randomized, placebo-controlled trial involving 399 adults demonstrated a 99% probability that the drug outperformed placebo. It is one of the first medications shown to provide meaningful benefit for long COVID fatigue, a condition affecting an estimated 65 million people worldwide with few proven treatment options.
A drug originally developed for spinal cord injury, KCL-286, has shown promise in treating Alzheimer's disease in mouse studies by repairing dangerous DNA damage, reducing brain inflammation, and targeting multiple disease pathways simultaneously. Separately, researchers found that many commonly used sweeteners can directly change the growth of gut bacteria, with over 100 cases where sweeteners behaved differently when combined with medications. A sugar-coated nanoparticle therapy also boosted survival against glioblastoma by 50% in mice.
The FDA approved Lipfendra, a first-of-its-kind oral medication from Merck that dramatically reduces cholesterol in patients who cannot tolerate statins or need additional therapy. Separately, an experimental Alzheimer's drug targeting the tau protein showed promise in a new study, and a blood test that can identify healthy people at high risk for Alzheimer's was validated. A Cyclospora parasite outbreak linked to produce has sickened hundreds across multiple states.
A large laboratory study has found that many commonly used artificial sweeteners can directly change the growth of gut bacteria, raising questions about their long-term health effects. The research tested multiple sweeteners including aspartame, sucralose, and saccharin on human gut microbes and found that each altered bacterial growth patterns in distinct ways. The findings add to growing evidence that non-sugar sweeteners, consumed by billions worldwide, may have unintended effects on the microbiome — the ecosystem of trillions of bacteria living in the human digestive tract that influence metabolism, immunity, and even mood.
A randomized controlled trial published in Nature Communications has found that semaglutide, the active ingredient in Ozempic and Wegovy, reversed biological age by an average of 3.1 years in adults with HIV after 32 weeks of treatment. The study of 108 participants used epigenetic clocks to measure aging, showing the strongest effects in the inflammatory system and brain, where aging was delayed by nearly 5 years.
The Ebola outbreak in northeastern Congo has surpassed 2,000 confirmed cases including 754 deaths, the World Health Organization reported Wednesday, as the crisis deepens with health workers at treatment centers going on strike over unpaid salaries and bonuses. Workers at Rwampara General Hospital in Ituri province walked off the job Monday, demanding months of back pay. The strike threatens to cripple containment efforts just as the virus spreads to new communities. A U.S. aid worker infected with Ebola has been flown to Germany for treatment after the Trump administration barred Americans from traveling on commercial flights.
Columbia University scientists have uncovered evidence that serotonin, the chemical best known for regulating mood, may accelerate the progression of a common heart valve disease. The study found that serotonin signaling can speed the development of mitral valve regurgitation, affecting millions of Americans. Separately, researchers announced that a non-invasive ultrasound treatment could help injured joints heal by breaking the cycle of chronic inflammation. The ultrasound therapy, tested in animal models, stimulated tissue repair without surgery. Both studies were published this week, offering new insights into cardiovascular and orthopedic medicine.
The FDA approved Casgevy, a CRISPR/Cas9 gene-editing therapy, for children as young as 2 with sickle cell disease and transfusion-dependent beta thalassemia, expanding from the previous minimum age of 12. The Vertex Pharmaceuticals therapy is now the first and only gene therapy available for this younger pediatric population. The expanded approval could make the treatment available to approximately 5,500 additional patients in the United States.
Researchers have discovered how colon cancer cells undergo an identity change that allows them to metastasize, opening new avenues for treatment. The study, published in Nature Cell Biology, reveals that tumor cells switch to a stem-cell-like state to travel through the bloodstream and establish new tumors. The finding could lead to therapies that block this transformation, potentially preventing metastasis in 90% of colon cancer deaths.
Researchers have identified the mechanism by which Alzheimer's disease kills brain cells, potentially opening new treatment pathways. Scientists discovered a 'hidden brain cell killer' that drives neurodegeneration in Alzheimer's patients. Separately, a study found that reprogramming brain immune cells could fight the disease. New research also revealed a surprising link between vitamin C and brain health, while another study found omega-3 supplements showed no cognitive benefit.